Video
Dr. Vokes on Biomarker Selection in Head and Neck Cancer
Author(s):
In Partnership With:
Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses biomarkers for immunotherapy in head and neck cancer.
Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses biomarkers for immunotherapy in head and neck cancer.
PD-L1 is an imperfect selection factor, says Vokes, but it can enrich in patients who are likely to respond to immunotherapy. There is no clear cutoff between patients who will and patients who will not respond, though, calling for a more selective biomarker.
